Amylyx Pharmaceuticals, Inc.

SecurityAMLX / Amylyx Pharmaceuticals, Inc.
InstitutionAldebaran Capital, Llc
Latest Disclosed Ownership197,892 shares
Latest Disclosed Value $ 2,750,699
Aldebaran Capital, Llc reports 0.31% decrease in ownership of AMLX / Amylyx Pharmaceuticals, Inc.

On May 7, 2026 - Aldebaran Capital, Llc filed a 13F-HR form disclosing ownership of 197,892 shares of Amylyx Pharmaceuticals, Inc. (US:AMLX) valued at $2,750,699 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 198,508 shares of Amylyx Pharmaceuticals, Inc.. This represents a change in shares of -0.31% during the quarter. The current value of the position is $2,831,835 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F AMYLYX PHARMACEUTICALS COM 03237H101 197,892 -616 -0.31 2,751 14.73 2.1027
2026-02-12 2025-12-31 13F AMYLYX PHARMACEUTICALS COM 03237H101 198,508 -5,966 -2.92 2,398 -13.71 2.1502
2025-11-10 2025-09-30 13F AMYLYX PHARMACEUTICALS COM 03237H101 204,474 -13,353 -6.13 2,779 99.00 2.5525
2025-08-12 2025-06-30 13F AMYLYX PHARMACEUTICALS COM 03237H101 217,827 -41,426 -15.98 1,396 52.24 1.3778
2025-05-13 2025-03-31 13F AMYLYX PHARMACEUTICALS COM 03237H101 259,253 -3,500 -1.33 918 -7.65 0.8680
2025-02-12 2024-12-31 13F AMYLYX PHARMACEUTICALS COM 03237H101 262,753 -7,050 -2.61 993 13.62 0.9439
2024-11-13 2024-09-30 13F AMYLYX PHARMACEUTICALS COM 03237H101 269,803 0 0.00 874 70.70 0.7979
2024-08-13 2024-06-30 13F AMYLYX PHARMACEUTICALS COM 03237H101 269,803 269,803 513 0.4773
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.